Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Just saw that HOOKIPA is selling off some of their oncology programs to NeoTrail Therapeutics. They're handing over HB-200 and HB-700, which are basically their immunotherapy shots for cancer treatment. The deal got signed back in January and should wrap up sometime this quarter.
So HB-200 is the one they've been testing for HPV-related head and neck cancers, and it showed some decent results when combined with pembrolizumab last year at that SITC conference. Got Fast Track status from the FDA too. Then there's HB-700, which targets KRAS-mutated cancers like lung and colorectal stuff - that one got IND clearance from the FDA last year and they've already finished manufacturing the trial materials.
Mark Winderlich from HOOKIPA said they're happy the development will continue at NeoTrail. Honestly makes sense - they still have HB-300 for prostate cancer, HB-400 for Hep B, and HB-500 for HIV in their pipeline, so they're not completely stepping back from immuno-oncology.
HOOK stock closed yesterday at $1.04, up about 4.5%. It's been bouncing between $0.72 and $1.96 over the past year. Interesting move to offload these programs - wonder if they're focusing resources elsewhere or just needed the cash.